Patent ID: 9603932
Date: 2017-03-28
CPC Classifications: A61K,C08G

Claim:
1. An intravaginal drug delivery device comprising: a polyurethane copolymer having a number average molecular weight ranging from 50,000 to 350,000 g/mol and a swollen hardness of at least 30 A, the copolymer having the structure according to formula (I): wherein, SS1, SS2, and SS3 denote soft segments, with SS1 being a polyether diol selected from polyethylene oxide (PEO) diol, polytetramethylene oxide (PTMO) diol, polyhexamethylene oxide diol (PHMO), polypropylene oxide (PPO) diol, copolymer of ethylene glycol and propylene glycol (PEG-co-PPO) diol, and mixtures thereof, SS2 being a hydroxyl or amine-terminated silicone polymer having a number average molecular weight ranging from 500 to 5000 g/mol, and SS3 being a soft-segment selected from polycarbonate diol and polyester diol and mixtures thereof, HS denotes a hard segment comprising a diisocyanate selected from the group consisting of hexamethylene diisocyanate (HMDI) and isophorone diisocyanate (IPDI) and combinations thereof, x and z are the same or different and each is an integer equal to or greater than zero, y is an integer equal to or greater than one, and at least two of x, y, and z are not zero; and SME1 and SME2 can be the same or different and each denotes a surface modifying endgroup comprising a methyl polyethylene glycol (MPEG) having a number average molecular weight ranging from 200 to 8000, linked to the polymer via a urethane or urea bond resulting from the reaction of an amine- or alcohol-terminated surface modifying end group with an isocyanate group, and at least one hydrophobic pharmaceutically active substance and at least one hydrophilic pharmaceutically active substance, said pharmaceutically active substances being homogenously distributed throughout the polyurethane copolymer.